Nufarm Limited (NUF) Earnings Call Transcript & Summary
May 19, 2022
Earnings Call Speaker Segments
Operator
operatorWe appreciate everyone being on the line, and welcome to Nufarm Limited’s First Half 2022 Results. Everyone attending is in listen-only mode for now. A presentation will be given, and after that we’ll hold a question-and-answer session. Should you want to pose a question, press the star key and then the number one on your telephone keypad. At this point I’d like to pass the conference to Mr. Greg Hunt, CEO. Please go ahead.
Greg Hunt
executiveThanks, Noah, and good morning to all of you. We appreciate you being here and welcome you to today's session. First, though, I want to point you toward the disclaimer located on page two, especially the part dealing with forward-looking statements. With me this morning is our CFO, Paul Townsend, and Brent Zacharias, our Group Executive, NuSeed — many of you will recognize him — is with us from Canada and will cover the Seed Technologies result. For Nufarm, this is a very strong result, with earnings higher across every one of our key measures. We've done exceptionally well, seizing on strong industry conditions while steering through global uncertainty and volatility. Clearly, favorable seasonal conditions and higher grain prices have worked in our favor. That said, we are also seeing the payoff from our transformation and performance improvement program of recent years. A deeper, broader emphasis on core Crops and key geographies is generating improved returns out of our Crop Protection business. In Seed Technologies, revenue kept growing in the core Seeds portfolio, and we kept reaching major milestones across our Omega-3 and Carinata growth platforms. Nufarm's outlook stays positive, since industry trends and conditions are highly supportive of growth.
Greg Hunt
executiveFeeding a growing population is a basic necessity, and Nufarm contributes to that goal. The prospects for the rest of this year look good as well, and I'll go into more detail on that later in the presentation. The numbers tell the story on their own. Revenue rose 31% to AUD 2.2 billion, and underlying EBITDA climbed 41% to AUD 330 million. Thanks to this outcome, we've been able to declare an interim dividend of AUD 0.04 per share. Our balance sheet is in good shape, and Paul will say more about that shortly. Put simply, this was a very strong interim financial result. That strength doesn't come down to market conditions alone. It reflects how we've managed through the current economic climate, brought forward new products and moved them ahead, and hit our milestones. And that's in spite of pressure from higher raw material prices, plus global supply chain and logistics challenges. Take our choice five years ago to set up a procurement hub in China — it has helped us lock in supply for our customers even with backlogs caused by COVID-related port closures and logistics difficulties. The money we've put into our supply and manufacturing sites is paying off in tangible ways for the business and for our capacity to supply customers dependably.
Greg Hunt
executiveWhen it comes to Ukraine, supporting our people has been our top priority. We've recorded a prudent provision against assets held in that country, staying within the range we guided earlier. Crucially, we keep moving forward, pushing our product and technology pipelines ahead. Our Crop Protection pipeline is still robust — more than 150 registrations or label-use expansions were granted in the half. Together with the new product launches we covered at our February Investor Day, that shows how healthy the pipeline is and supports our revenue ambitions. Through our Value Beyond Yield investment, we're developing new plant-based Technologies. Growth in the Seeds business, the Carinata agreement with bp, and repeat Omega-3 canola sales to customers in Chile all underpin the growth ambitions in our five-year plan. We also completed the high-yield bond refinance in the half, which further strengthens our balance sheet and delivers $9.8 million of interest savings each year. All our business segments performed impressively given the market and regulatory conditions prevailing. The combined result confirmed our diversity strategy — one aimed at minimizing risk while maximizing returns. Even with EUR 26 million in revenue impacts from product deregistrations, Europe posted a very solid result, in line with the strong result we delivered last year.
Greg Hunt
executiveThat also shows how valuable the portfolio we acquired is, since it delivered 42% of gross margin within our branded business. At Seed Technologies, demand was robust right across the portfolio. In the core Seeds business, growth carried on the momentum we built in financial year 2021 when we released new hybrid varieties. We've also kept reaching key milestones on both our Omega-3 canola and Carinata biofuel feedstocks, and Brent will speak about those shortly. This slide lays out what drove revenue and earnings growth, and three of our business segments delivered meaningful uplift in revenue as well as earnings. As I mentioned at the start, seasonal conditions benefited us in every region. That said, the strategic initiatives we've put in place over the past few years have helped push earnings growth. I'll return to the outlook later, but for now, I'd like to pass things to Paul so he can go through our financial performance.
Paul Townsend
executiveThank you, Greg, and good morning to all of you. Strong demand for our Crop Protection and Seed products drove the outstanding half-year financial outcome, with higher revenues stemming from favorable commodity prices and trading conditions in every region. The 31% revenue increase includes sales of AUD 76 million — sorry, AUD 183 million — at zero margin in the first half of 2021 through Sumitomo Chemical Latin America under the transitional services agreement. Underlying EBITDA rose 41% to AUD 330 million, while underlying EBIT climbed 66% to AUD 222 million. Underlying financing costs fell thanks to the effect of refinancing the U.S. dollar high yield bond notes, along with lower foreign exchange losses, partly offset by unfavorable foreign exchange translation on interest denominated in foreign currencies. For the full year, we anticipate interest expense of roughly AUD 50 million versus AUD 58 million in the prior corresponding period, reflecting reduced interest on the refinanced U.S. dollar notes. This naturally depends on movements in the A dollar versus the US dollar exchange rate. Foreign currency exchange losses declined despite currency volatility, especially in Eastern Europe. We are realizing the advantages of targeted initiatives to mitigate foreign exchange currency risk, such as expanding the hedging program and recapitalizing subsidiaries so they can cut their local currency exposure.
Paul Townsend
executiveDepreciation and amortization came in at AUD 108 million, up AUD 9 million, or 9%, driven by greater amortization on European products that have been discontinued along with commercialization of Seed Technologies IP products. For the full year, we expect depreciation and amortization to be materially in line with last year. Our underlying effective tax rate of 31% is now at the level we expect to settle at over the medium term, and it matches the full year effective rate in 2021. The average ratio of net working capital to sales stands at 27%, which is well under Nufarm's target of 35%-40% and represents an 8 percentage point improvement half-on-half. That shows how we've managed to bring down absolute net working capital even as sales rose substantially. Happily, supported by the excellent earnings, net debt and leverage both improved half-on-half. Although free cash flow is negative for the half, that's mostly because of the seasonal working capital buildup, which we expect to reverse in the second half, giving a positive free cash flow outlook for the year. With the positive earnings and cash flow outlook, plus our current loan leverage of 1.1 times, the directors have been able to declare an interim dividend of AUD 0.04 per share.
Paul Townsend
executiveThis dividend was declared within the framework of Nufarm's fresh capital management principles, and those principles will steer how we apply and allocate free cash flow. You'll find these principles in the appendices. We stay disciplined with expense management so that any increases line up with supporting our growth agenda. As the chart illustrates, the rises are tied to greater spending on headcount and other costs linked to our growth initiatives across Crop Protection and Seed Technologies. Higher selling and distribution costs came mostly from logistics rate increases and third-party sales commissions. There was also an increase in employee incentive provisions tied to the strong earnings outlook. Depreciation and amortization expense went up. Travel rose as we move out of COVID restrictions. Insurance increased because of market-related increases, and staff costs rose with CPI increases. The following chart illustrates, or reconciles, our underlying EBITDA to free cash flow. As a reminder, free cash flow is the cash the business generates before any distribution to shareholders. Clearly, EBITDA and net working capital are the dominant contributors to this bridge. On working capital, the main driver of the outflow is the seasonality of the business, and it relates predominantly to higher receivables stemming from greater sales over this period.
Paul Townsend
executiveThe seasonal pattern has been made more pronounced by the greater concentration of revenue in the first half, along with pricing. We expect the net working capital position to unwind during the second half, and we expect positive free cash flow generation for the full year. Because of that, the average ratio of net working capital to sales is a more useful measure for assessing how net working capital is managed, since it is calculated on a rolling twelve-month basis. As the chart shows, that ratio keeps getting better and now stands at 27%, well under our target range of 35%-40%. Although this is a great result for Nufarm, we will keep focusing on net working capital, and we'll need to strike a balance by ensuring continuity of supply, given the global logistics and supply chain challenges, and by optimizing our commercial relationship with our customers. On inventory and payables management, utilization of the supplier financing facility rose further during the half, largely because of increases in raw material prices. This facility remains an important element in strengthening Nufarm's relationship with key Chinese raw material suppliers, which helps secure product supplies in the current tight market conditions. Tax and interest payments of AUD 18 million and AUD 40 million came in as forecast, while CapEx investment of around 60 million is below expectations because of lower property plant equipment investment at Wyke, due to timing related matters influenced by COVID-19 challenges.
Paul Townsend
executiveTo get to a net cash flow figure for the group, you need to subtract ordinary dividend payments of AUD 15 million along with roughly 5 million in payments under the Nufarm Step-Up Securities. Moving on to the balance sheet. As you can see, net debt and leverage both improved half-on-half. On a rolling twelve-month basis, leverage sits at 1.1 times, which is below our core leverage target of 1.5 to 2 times, including leases, and for the full year it is expected to come in under 1 time. The company keeps very strong liquidity, with undrawn facilities at March 31 of about AUD 550 million and cash balances of around AUD 460 million. Lastly, the high-yield bond refinancing will deliver ongoing annualized interest savings of $9.8 million, as Greg alluded to earlier. The full monthly savings run rate occurs from March 2022 following the transition to the new arrangements. I'll now hand you back to Greg.
Greg Hunt
executiveThanks, Paul. Now I'll walk through some specifics on our Crop Protection business. Having a more varied product portfolio and geographic footprint is a major mitigant against earnings volatility. A lot of you are aware that our portfolio leans toward herbicide products growers require every single year, and that's complemented by a smaller share of insecticide and fungicide products with higher margins, where demand tends to fluctuate more. As we told you at the February Investor Day, we're putting investment into differentiated higher-margin products that complement our portfolio of foundational lower-margin products, and both matter to our growth aspirations. On geographic diversity, we keep a strong presence in the key markets where we think we can be relevant to customers and deliver solid cash returns for shareholders. Our growth ambition for the Seed Technologies business that we laid out in February will contribute to diversifying income streams over the years ahead. Moving to the geographical regions, APAC had a very strong year. A year ago, people asked us whether it could get any better than that, and this result clearly demonstrates it hadn't. Increased revenues, better margins, and reduced selling, general and administration costs produced a 45% rise in EBITDA.
Greg Hunt
executiveThis area covers our operations in Australia, New Zealand, the Croplands spraying equipment business based here in Australia, Indonesia, and our Malaysian operations, which help drive sales into other Southeast Asian nations. Our China joint venture is also part of this segment. To us, Australia and New Zealand matter a great deal. They serve as our home base, and we hold a leading position there. Over the past five years, the restructuring in the APAC region — during which we closed five factories, merged two brands into one, and took costs out of the back office — kept delivering synergies that will keep helping and continue to help the bottom line. Now that the reset of our manufacturing footprint and back office is finished, our attention has shifted to growing our portfolio. In financial year 2021, we brought a number of targeted products to the domestic market. One example is Terrad'or, a new proprietary herbicide that is highly active against key broadleaf and grass weeds resistant to glyphosate. Saracen, a different herbicide, when combined with our phenoxy products, produces a differentiated solution that is active on hard-to-control weeds in cereal crops. Both of these made a positive contribution to the first half result. As we laid out at our Investor Day in February, we are also collaborating with local institutions including the CSIRO and the University of Queensland on products to support Australian growers, and we expect those products to reach commercialization within the next 2 to 3 years.
Greg Hunt
executiveSeasonal weather will affect us annually, yet every one of these products and innovations gives us a strong foundation to build on. As I noted before, getting the earnings base in Europe reset stood as a top management priority during financial year 2021, and I'm delighted to report that Europe keeps turning in robust results. When we reported our 2021 result, I stated that over the near term the portfolio we already hold can hold earnings steady under normal seasonal conditions, regulatory headwinds notwithstanding, and that is exactly how things have played out. It's a good result, but more work remains. We've put substantial investment into this region across the past 3 years, and the present return doesn't justify that outlay. Even with EUR 26 million in sales lost from products de-registered during the period, Europe posted revenue growth of 6% and an earnings outcome precisely matching the first half of 2021. Sales from the acquired portfolios are rising, and though separating their earnings from the wider business grows harder, they delivered roughly 35% of total gross margin and, as I mentioned earlier, 45% of the branded business.
Greg Hunt
executiveOur North American operations are off to a great start this year, posting 49% revenue growth and a 167% increase in EBITDA when measured in U.S. dollars. Every part of this segment delivered strong growth, with revenue rising in Crop Protection across the U.S., Canada, and Mexico — largely fueled by robust corn and soybean prices, while market conditions generated substantial demand. With COVID restrictions letting up, the Turf and Ornamental business came back to more typical volumes, and we recorded an improved product mix alongside volume growth across all of the business's key segments. The sizable gains in both earnings and margin show the payoff from what we've invested in domestic manufacturing capability in North America. Being on the ground lets us supply locally and build tighter relationships with our customers. We've kept their confidence through what has been a very tough stretch for them on the supply side. Prudent, efficient expense management on an ongoing basis has also fed into the wider earnings margins. In our view, channel inventories in North America have stayed at comparatively low levels, mirroring the global and domestic supply disruption that hit the whole industry this year.
Greg Hunt
executiveFor most of the orders we expect in the second half, we already hold enough stock in our warehouses or in shipments currently at sea. At this point I'll hand things over to Brent for the Seed Technologies portion. Thank you, Brent.
Brent Zacharias
executiveThank you, Greg, and good morning to all of you. As Greg noted, we kept growing revenue in our core Seeds portfolio and achieved significant strategic milestones across our omega-3 and carotenoid platforms. We remain firmly on course to reach our strategic aspirations. Revenue from Seed Technologies rose 28%, and orders for Seed were also higher by 24% in 2026. Those are very strong results and they reflect broad-based gains throughout the entire business. Among the key growth drivers in our core Seeds business were robust sales of new hybrid canola varieties in Australia, South America, and Canada. Sales of our newer sorghum varieties continued to rise in Brazil and the USA, and demand grew for sunflower varieties in both North and South America. The first half also brought important milestones in omega-3 and carotenoid. These results clearly confirm NuSeed's value to the overall strategy. NuSeed earnings remain strongly weighted toward 2021, mainly because of the timing of planting and harvesting for our Crops in the respective geographies. Let me look a little more at our Omega-3 platform. Over the first half, demand for salmon kept growing. That helped drive higher orders for Aquaterra from existing customers that produce salmon feed, and Aquaterra has now become an established Seed input for the Chilean aquaculture market, with repeat orders and strong positive feedback from customers.
Brent Zacharias
executiveWith Aquaterra expanding, we're sharpening how we source and move product too, starting with the inaugural oil shipment. Nutriterra, our Omega-3 product for human nutrition, hit a number of milestones previously as well. The Food and Drug Administration (FDA) confirmed it's a safe food ingredient. That clearance, paired with Nutriterra's prior acceptance as a new dietary ingredient, should strengthen talks with prospective partners about a commercial launch of Nutriterra across human nutrition markets. We are also signing up growers right now to satisfy the demand we anticipate going into next. We're getting ready to roll out our second-generation. Those hybrids should deliver a substantial. Demand remains very strong in both markets as we see it. Being the top supplier worldwide of plant-based omega-3 means we're well placed to seize these opportunities. During February's Investor Day, we laid out further key milestones and kept our attention on the coming steps — growing the customer base, scaling operations, widening margins, and securing additional significant market approvals as the key outcomes for the coming two to four years. Now shifting to Carinata. The first half's standout was signing our long-term strategic offtake and market development agreement with bp.
Brent Zacharias
executiveFor this program, we view it as a transformational development, and it strongly validates the potential of NuSeed Carinata as an advanced, non-food agricultural feedstock that is sustainable for producing biofuel. The agreement, with an initial term of 10 years, lets us quickly speed up development and expansion of our grower network, our channel partners, and our supply chain partners so we can deliver Carinata oil to bp or its affiliates. This year we have begun validation and development work with Carinata on all four continents, and we are expanding our production base in Argentina and Uruguay. Next, we will be launching Carinata in hybrid Seed genetics, and we intend to expand supply from our current base in Argentina and Uruguay in 2022. Launch in the USA in 2023, followed by Brazil in 2024, while at the same time advancing further product developments in Europe and Australia for future launch. Along with our Omega-3 oil and our strongly performing core Seeds portfolio, Carinata will be a key growth platform over the coming years. Thank you, and I will hand it back to Greg.
Greg Hunt
executiveThanks, Brent. I noticed the audio might have been somewhat hard to follow during one section of your presentation, Brent, especially the part on Omega-3. It came through much more clearly once you got to Carinata. I imagine we'll have an opportunity during Q&A to revisit and perhaps reinforce a few of the points you raised regarding Omega-3. In any case, I'd say there have been some quite encouraging developments during the last few months, which, as I mentioned before, leave us with, you know, ongoing confidence in what these Technologies could be worth, as we've discussed in our five-year plan. So now, turning to the outlook. As I noted earlier, you know, the agricultural landscape keeps shifting, and there are major mega trends that I believe are worth recalling, since they keep reshaping our industry. The first big trend is the sharp rise in food demand anticipated over the coming 30 years, fueled by population growth. The following mega trend is the push to get more productivity out of the same land while ensuring we keep enhancing that land. Our industry, much like many others, is also confronting a strong trend toward a more Sustainable future.
Greg Hunt
executiveConcern about reducing our environmental footprint and enhancing the state of our oceans, air, and soils keeps intensifying. And finally, cutting-edge technology is going to assist us in discovering answers to those challenges, while also creating fresh possibilities. A renewed Nufarm sits right at the heart of this transformation, and the enhancements we have delivered across the company during the last five years, together with the capital we have committed, leave us strongly placed to seize both current and newly arising growth openings. During our Investor Day in February, we set out our five-year growth ambitions in far greater depth, and it gives me pleasure to restate those goals. Sustainable annual revenue of AUD 4.6 billion by 2026, with Seed Technologies delivering roughly AUD 650 million in 2026 at very strong margins. We are making solid progress toward that outcome and are plainly enthusiastic about the growth potential ahead. Nufarm stands to gain from the move toward more sustainable agricultural solutions. We help our growers get more output from fewer inputs, while supplying products that assist them in adjusting to climate change and in limiting unintended environmental effects. Innovation and technology are going to power Nufarm's growth and sustainability. This slide highlights a number of the innovations and Technologies we currently have in development.
Greg Hunt
executiveLike I mentioned, we gave some specifics back in February. I don't plan to walk through those specifics again today, but partnering with and investing in organizations that share our thinking is a key part of our strategy for advancing our aspirations. Now to the outlook. Industry conditions continue to be very favorable going forward. The outlook for grain prices is still positive, and favorable seasonal conditions across our regions are driving sustained strong demand for Seed and Crop Protection products. We expect strong earnings for the full year. As I've said before, given the strength of forward sales fueled by global uncertainty and volatility, full-year results will be weighted proportionally toward the first half. While some easing of these favorable conditions will likely happen in future periods, several factors support our growth aspirations through seasonal cyclicality. Recent global issues, including the conflict in Eastern Europe, have raised awareness that Crop Protection is a vital component in ensuring global food security. This is encouraging agricultural production in other geographies and tightening global supply. Over the longer term, we believe the underlying dynamics of our key markets are strong and the opportunity before us is significant. The next phase of our growth and evolution has begun, and a large part of that is about innovation and technology.
Greg Hunt
executiveThe technologies we've put money into so that our industry's future requirements can be met are going to make up the central part of our growth engine — the core of it. Thanks to everyone, and I'm glad now to give things back to Nia for some questions.
Operator
operatorThank you. Should you want to pose a question, kindly press star one on your phone and hold until your name is called. To withdraw your request, press star two instead. In case you're using a speakerphone, lift the handset before asking. Our first question is from John Purtell of Macquarie Group. Please proceed.
John Purtell
analystOh, hello there. Is our audio coming through clearly for everyone?
Greg Hunt
executiveOkay, that works. Thanks, John.
John Purtell
analystThanks, Greg. I had a couple of questions. Thank you. Regarding the Europe result and that EUR 26 million sales impact, what was the profit impact tied to it? I know you mentioned — I believe it was a EUR 15 million profit impact you expect for the full year. Is that still roughly the order of magnitude you're anticipating as a headwind?
Paul Townsend
executiveYeah, pretty much. Good morning, John — this is Paul Townsend speaking. The effect comes to roughly AUD 15 million. That is the margin hit for 2016. Really, it is just the total, or the direct cost, for most of the first half. That entire run-out really falls in the first half, since during the second half of last year we had already begun to see some of that revenue decline.
John Purtell
analystUnderstood, thanks. On that second point about North America — clearly a strong result. Would you describe it as somewhat of a recovery following last year? Seasonal conditions obviously weren't perfect, and we still faced drought in Canada this time around. Do you expect that momentum to carry into the second half there? Historically, it has actually leaned a bit more toward the second half, or at least that's what we saw last year.
Greg Hunt
executiveJohn, as I mentioned before, I think low general inventories created really strong demand and sales during the first half, which pulled sales forward. The season is running somewhat late there, with dry conditions in the southern states of Texas. Demand has softened a bit in April and May. At this point, I wouldn't expect the second half to be as strong as last year. Supply chain logistics mean supply will stay tight. I just don't see it being as strong this year as it was last year.
John Purtell
analystUnderstood. One last thing for Brent. This is about the main milestones we ought to watch regarding Omega-3 and Carinata across the coming 12 months.
Brent Zacharias
executiveOkay, that's great. Thanks, John. So as far as what comes next, I'll begin with Omega-3. It might not be coming through — I believe there was some noise on the line while I was speaking. Right, the next steps we're really concentrating on involve expanding the customer base beyond what we already have today in Chile. We're beginning to scale up operations in terms of some of the efficiencies we can capture as volumes grow, which should lead to improved margins. And then there's securing additional import market approvals as we work to complete the remaining regulatory clearances globally. I'd say those are likely the main near-term milestones for Carinata. Oh, sorry — for Omega-3. When it comes to Carinata, our focus right now is really on expansion following the announcement of the bp deal. Much of that centers on growing supply. As I pointed out, we have a very step-by-step plan: launching in multiple countries now, scaling from those countries, and then collaborating with our value chain partners to fulfill that bp contract. Another point I might return to — looking at both of those businesses along with the core Seeds businesses — as we laid out at the Investor Day in February, we hold an aspiration to reach AUD 600 million–AUD 700 million in revenues at 20%–25% EBITDA margins by 2026.
Brent Zacharias
executiveWhat I'd say is this: with all three of those platforms now in the commercial phase and scaling up, the progress we're seeing means each of the three is a genuinely meaningful contributor to that aspiration. I hope that answers your question, John.
John Purtell
analystI appreciate that.
Greg Hunt
executiveI think perhaps John could expand slightly, particularly regarding Omega-3 and how we're approaching it relative to the earlier guidance, so to speak, or the information we provided before COVID. This reflects how Brent and I have been viewing things. If we truly consider financial year 2022 as essentially a sell-out year for Omega-3, basically, so to speak, the inventory from calendar year 2020. We didn't plant a Crop during calendar year 2021, and this year, calendar year 2022, the Crop we're planting at present, we believe will satisfy demand, so to speak, the demand in calendar year 2023, and after that, in calendar year 2023, the acres to be planted will truly be set according to the reforecast demand at that point, which we'd anticipate having rebounded from COVID's effects and ought to be above 2021 and/or 2022, if that's helpful.
John Purtell
analystI appreciate that.
Operator
operatorThanks. We’ll take the next question from Evan Karatzas at UBS. You have the floor.
Evan Karatzas
analystHey Greg — and Brent, you both kind of brought this up — the rise in worries about food security worldwide. Has that affected, or shifted at all, I suppose, some of those European regulatory hurdles you've been dealing with, I guess, across the last few years? Have you noticed any difference in that, you know, over the past, you know, 3 to 4 months, 6 months?
Greg Hunt
executiveSure, that’s a fair question. There’s nothing we can really identify with specificity. I mean, some European leaders have definitely been saying that those targets might need to be revisited. As you’re aware, the Farm to Fork targets haven’t actually been legislated, and I’d just like to remind everyone that they were based on the average of 2015, 2016, and 2017. So quite a lot has been accomplished over those last 5, 6, 7, 8 years. And I think, again, the way we look at it is that we understand the impact in this current financial year. We know there are additional impacts coming in the next financial year. Again, the challenge is for the new portfolio and other product launches to really be able to offset the revenue we lose from those regulatory exits. Then we’re really focused on 2024, 2025, 2026 when we have—these are some of the products we discussed at the Investor Day. If you go back and look at that calendarization, you’ll see that in 2024, 2025, 2026, we have quite a few of those new product introductions coming through.
Greg Hunt
executiveWe also have that distribution agreement in place with Sumitomo — it isn't exclusive, but it covers distribution for a number of those higher-margin fungicides and insecticides. Honestly, to put it precisely, we aren't seeing anything meaningful or any shift in outlook coming from the bureaucrats or the regulators.
Evan Karatzas
analystRight, okay, that's clear. So if we set aside the corporate piece and focus on the underlying 26% revenue growth — Paul, this might be one for you. Could you break down, roughly, how much came from price versus volume and mix, and give us any sense of direction or guidance on what price contributed as a share of that revenue growth?
Paul Townsend
executiveOn the corporate side, revenue came in at AUD 183 million, and that's what we—
Evan Karatzas
analystNope. My apologies — that figure leaves out the company’s revenue.
Paul Townsend
executiveIf we set aside corporate revenue, price is the primary factor, though there's also some contribution—and I think Greg mentioned this when discussing the individual regions. We've seen a bit of volume growth in certain key segments, along with mix. So it's really all three working together, and while we aren't breaking it out specifically, price has clearly been the biggest driver of growth. You can see that in our period results announcement too—price has, you know, been by far the largest contributor, but we've definitely had some solid volume growth in a few key segments and a nice improvement in profitable mix.
Evan Karatzas
analystOkay, I appreciate everyone taking the time today.
Operator
operatorThanks. Our following question is from Grant Saligari at Credit Suisse. You have the floor.
Grant Saligari
analystGood morning, and thanks. Greg, those are strong, solid results — really good to see. On Europe, I realize there's obviously some attention on that during this call, but regarding Europe, could you lay out a bit more specifically the things you believe you can do to extract somewhat more performance from Europe? Perhaps also, with respect to the current result, how would you frame that in terms of whether this is a good, poor, or above-average Crop and general market conditions? In other words, is this indicative of what we should expect for a normal Crop and market conditions in Europe?
Greg Hunt
executiveApologies — I'll take that last item first. I'd call it pretty ordinary. What I mean is, conditions vary quite a bit across Europe. As you're aware, it spans.
Grant Saligari
analystYeah.
Greg Hunt
executiveSo, it's a big territory with varying seasonal patterns across it, and honestly, I'd call conditions normal — that seems like a reasonable way to put it. Looking ahead over the coming 4 or 5 years, there's still additional work we can accomplish within our supply chain. We have a capital program aimed at investing in our Wyke operation, which truly serves as a worldwide facility for our specialty phenoxy and MCPA, where we hold a leading global position. That sits within the European result. I expect it to contribute further. We also have formulation sites at Gaillon and Linz, and there's more we can accomplish there — essentially the same thing we've already carried out in North America, so to speak, to upgrade our supply chain, formulations, logistics, and warehousing. Quite a lot of work lies ahead. Once those foundational parameters are set correctly, the genuine driver of growth then comes from the portfolio. As you're aware, building those products and securing the registrations takes time. The acquired portfolio has carried us and will keep carrying us. Absent taking some other action, such as acquiring certain products, I don't foresee a meaningful improvement.
Greg Hunt
executiveRight now, I don’t have clear visibility of anything specific. What it really comes down to is simply that hard work—cleaning up the business, extracting a bit more margin wherever possible—with our attention fixed on, well, really 2024 and 2025, when we begin to see the effect, the genuine effect, of what we’ve discussed, you know, again, going back to the Investor day and with, you know, the Sumitomo portfolio. I genuinely believe additional opportunities will present themselves to us, you know, during that stretch of time. I’m just unable to be specific about them at this point.
Grant Saligari
analystOkay. Still on that North America number — the gain there really stood out, and it actually came even with Canada dealing with, you know, drought conditions. Things weren't entirely favorable there. Do you see that performance level in North America as sustainable? Again, I suppose it's a similar question: what more do you think you could do in the North American market to strengthen your position?
Greg Hunt
executiveSo once more, in contrast with Europe, the real effort — or, if you prefer, the demanding work — on the supply chain side, and we have discussed those facilities previously. The insecticide/fungicide site at Alsip, a state-of-the-art plant, is doing well. Greenville had its commissioning just 18 months back. It is going extremely strongly indeed. The effect of that on our internal efficiencies, and equally on our capacity to supply customers dependably, should not be underestimated. Additional work remains for us at Chicago Heights, and that is going to get done over roughly the coming two or three years. After that, it is genuinely a question of sizing the growth and deciding if further Greenville-style operations are needed. We are possibly considering something in Canada or something on the West Coast. Those are the kinds of things that make a difference. Once more, in the end it comes down to what the portfolio delivers, and that is where attention is directed. I could not agree more. The result has been outstanding. I would not treat this as anything close to normal. There was a fairly pronounced tilt toward the first half, given supply uncertainty and volatility. Still, I do believe that if you examine how North America has performed across the past four or five years, there has simply been continual growth.
Greg Hunt
executiveThere's no reason to think that won't keep going, as I see it. If you adopt a view spanning 4 or 5 years instead of looking half-over-half, that's likely the better lens through which to examine it, I think.
Grant Saligari
analystYeah, alright. That's quite useful. Solid outcome.
Greg Hunt
executiveI appreciate that.
Operator
operatorThank you. Our next question is from Richard Johnson at Jefferies. Please proceed.
Richard Johnson
analystMany thanks. Greg, could I go back to what was said before regarding volume growth during the first half? Maybe you can help me get a clearer picture of just what sort of volume growth you had. I'm asking because it seemed as though you were downplaying volume somewhat, and that comes as a surprise considering the favorable conditions you've had — seasonal conditions, obviously, in core markets. I'm simply trying to grasp that a bit better, and then also to reconcile how we ought to think about today's volume level against the long-term trend, which is clearly population growth, and that's a much lower figure.
Greg Hunt
executiveI think that's really the right way to frame it, Richard. On the trends we're seeing right now, we're going to end up at a certain revenue level. Part of that comes from volume, part from pricing, and part from product mix. Volume is growing in a few of those segments, especially in North America, I'd say. In the other markets, price has been the bigger driver. At some point — and as I've mentioned before, nobody rings a bell at the top or the bottom — we're beginning to see active ingredient, or raw material, prices come down. Whether that shows up in the second half or instead in the first half of 2023, I honestly can't say. At some point we will see a correction in pricing. The volume story, then, really ties back to the portfolio and what you have to sell. That's honestly where we're focused when we look at the five-year plan. It's entirely about having Products that accomplish two things. It keeps you relevant with your customers, and that drives volume, but it also — the mix begins to improve quality of earnings and the margin percentage as the volume of higher margin differentiated product starts to bite.
Richard Johnson
analystAppreciate that—very useful. One quick item for Brent regarding Carinata. Over roughly the past day, Qantas has been publicly discussing how synthetic fuels might take the place of biofuels. What I'd really like to ask is your perspective on that, and whether your longer-range assessment of how large the addressable market could be has factored it in.
Brent Zacharias
executiveRight, thanks Richard, and thanks for raising that. So, when we look at how the market is shaping up, the size of the opportunity is clearly enormous given the demand — whether we're talking renewables, biofuels, or other technologies in aviation. We're certainly conscious of all this and have been keeping up with how every other kind of technology is developing. That said, one useful benchmark to keep in mind might be the industry itself — IATA, the International Air Transport Association — which has been issuing guidance on what part Sustainable Aviation Fuel will play going forward. Their projection is that, of all the volume that shifts toward new fuel types or technology, 65% will have to be Sustainable Aviation Fuel, derived from veg oil or other plant-based sources. At the same time, 35% of a very large market is still looking at new and other technologies that will arrive further down the line. From our conversations with the Aviation industry, I'd say the genuinely hardest challenge to crack is long-haul flights and transport, and that appears to be where most of the airlines are really focused today.
Brent Zacharias
executiveYou know, I'd say it's fair to describe them as examining every kind of technology out there as they work on making that transition and shifting toward the future.
Richard Johnson
analystNo, that’s useful. Thanks. Then, just briefly on Omega-3: are the continuing COVID-related shutdowns in China still holding back growth for the wider market — the salmon market?
Brent Zacharias
executiveIt's interesting — we've witnessed a really robust rebound across every salmon market. Prices have come back. Margins, too, have recovered in most salmon markets worldwide. I'm not sure whether we've already felt some of the near-term effects from China at this point, but Europe, North America, and the rest of the world have performed very strongly. Right now, we're seeing genuinely solid results when it comes to growth and demand on a global basis. I think everybody is watching those developments closely and considering what impact they might bring. It remains a dynamic we need to monitor quite carefully. As things stand, the market looks really healthy.
Richard Johnson
analystMuch appreciated — that clears things up nicely. I have nothing further to ask.
Paul Townsend
executiveRichard, one more thing I'd add — Brent may not have come across those Qantas announcements. Beyond what Brent mentioned, I'd also note that Carinata is an option available right now, and I believe it will keep playing a part until those new technologies are developed and/or commercialized.
Operator
operatorThanks. Our following question is from James Ferrier at Wilsons. Go right ahead.
James Ferrier
analystMorning, everyone. Appreciate you making the time, and well done on the result. For the first question, could you give us some added detail on the AUD 190 million of CapEx you expect for the full year? Perhaps break it out, stay-in-business versus growth, or alternatively fixed asset versus intangibles.
Paul Townsend
executiveYes. Morning, James. At the full year we kind of gave the indication that of that 190, roughly AUD 150 million is stay-in-business and 35 million was expected to go into Wyke essentially. There are several projects at Wyke around improving and raising capacity in the Provimi Tolle Probiotics area. That's where the split sits between stay-in-business, if you like, and growth. Within that 150, though, it's roughly about 100 million of intangible spend and then 50 million of PPE investment — stay-in-business, probably plant and equipment investment. Of the 100, about 60% is Crop Protection and 40% is Seed Technologies. As we called out, there's some growth CapEx in there, whether that's global extensions or other expansions of our IP, if you like, inside that 100 — to isolate growth CapEx from some of the regular side of that steady business, for purposes of, you know, how people should think about what our CapEx is.
James Ferrier
analystThat's quite useful, and it brings me to what I want to ask next. Within Crop Protection, intangible CapEx comes to roughly AUD 60 million. Across the past 10 years, that figure has probably sat in the range of, say, 40 to 60. Is that level of spending appropriate? Is it sufficient not only to hold Crop Protection revenue at its current level, but also to help enable the AUD 500 million to AUD 600 million of net new revenue in Crop Protection that Nufarm is targeting by 2020?
Paul Townsend
executiveYeah. I’m not sure whether you joined the Investor Day call, James. That was something that came up there, and basically, we expect the Crop Protection investment — so the ratio as it stands today — to keep, if you like, holding at that ratio. I believe it’s roughly 3.5% of sales. That will carry on going forward. That way we can, if you like, back the growth in Crop Protection revenues that we had identified at the time of the Investor Day. Yes, there is a growth component. The growth in that 60 to support the growth in Crop Protection.
Greg Hunt
executiveYeah, James, if I could just build on that — we mentioned 200 projects in the pipeline, and 22 of them are especially important to us. What I'd point out is those 22 projects are already funded within that CapEx program and have cleared Proof of Concept. We have fairly solid visibility into what those projects will deliver under that five-year plan.
James Ferrier
analystGreat, Color, thanks for that. On the North American side, could you quantify the return toward more typical demand levels in the Turf and Ornamental segment?
Paul Townsend
executiveRight. We aren't going to address that point directly. What I can do is build on Greg's remarks and say that this outcome isn't typical. Under normal circumstances, you know, at a high level, we tend to see roughly a 50/50 division across the two halves. In the prior year the weighting leaned toward the second half, driven by all those supply constraints, the polar vortex, and so on and so forth, which hit the first half. The current half simply isn't a like-for-like comparison, since there's a pull-forward plus higher demand from customers eager to secure their foot on product. When we consider North America, typical conditions show more of a 50/50 split, weighted toward the first half and second half.
James Ferrier
analystAlright, thank you. This last one is probably for Brent. I completely grasp the longer-term direction for Omega-3 and, you know, what you plan to do with planting and the outer years when it comes to demand. For the near term, though, I'd like to find out what kind of feedback you're receiving, what kind of reception growers are giving to planting Omega-3 Seed within the program, given how high cash Crop canola prices are right now, and then how that could affect your likely acreage this year.
Brent Zacharias
executiveYes, that's a fair point. Clearly, commodity prices have seen considerable volatility and escalation. Perhaps to widen the question a little — the effect of canola prices. Growers, of course, anticipate receiving more for base canola, and beyond that we pay premiums so they'll grow it as an Identity Preserved product. Truly, the issue comes down to whether our business model lets us stay competitive at the farm gate while passing those extra costs along to our end use customers. What I'd say is this: on the end use customer side, they get it, since they purchase fish oil, which is trading at record levels. They purchase canola oil too and are fully aware of the volatility we're seeing in world markets at the moment. What I'd say is that much of this comes down to being competitive at the farm gate so we can secure the acres, and then being able to land that product at higher values in the end use markets.
Brent Zacharias
executiveWe have in fact already demonstrated that through our capacity to raise prices in a matching way, you know, alongside the end-use market. That is really part of how the business model is managed. I don't really view canola or commodity prices as a constraint, you know, on the potential for acquiring growers. What's probably most exciting for us is delivering, you know, better and continuously improved genetics to the farm gate. You know, I think I've said before that we are now transitioning to our second generation of genetics, and we'll be launching some of those, this year in 2022, to be planted in 2023 for oil in 2024. You know, it's all coming together rather nicely, I'd say, in terms of being able to balance all of those factors.
James Ferrier
analystThanks, Brent. That's very helpful. Calla. Thank you.
Operator
operatorThanks. We move to our following question, which is from a private investor, Matt Perry. You have the floor.
Matt Perry
unknownHello. Omega-3 canola is something I'm especially focused on, along with how much market share you're gaining. Could you give me your estimate of a sensible TAM, and what portion of it you'd expect to be able to win?
Brent Zacharias
executiveSure, thanks for asking that. Well, it really hinges on what you consider the market to be — the one you're actually taking part in. At our Investor Day, one thing we highlighted was that during our initial year of commercial operations — or roughly 15 months, I should say — we figured we'd captured around 4% share of the Chilean salmon feed market. That detail was shared back in February. We feel quite good about it, considering we'd only just started selling commercially, and it also shows how much room to grow exists with that product. Coming back, probably, to how you assess the market's size and how big the opportunity is: in an unconstrained model, we also made projections covering the coming 10 years — meaning when we're able to deliver extra omega-3 oil through this kind of technology into a market that has been limited by having only a flat quantity of fish oil on offer. Our view is that demand will reach roughly 2x today's fish oil market, expanding from 900,000 tons up to 1.8 million tons. The value pool we could tap into using this technology comes to roughly AUD 850 million in EBITDA, measured in AUD.
Brent Zacharias
executiveSo look, this is a really big market for us to be involved in, and the way we see it is that today we're plainly the leader in new Technologies supplied to that market, and we keep believing we'll hold on to that leading position. Hopefully that answers your question.
Matt Perry
unknownYes, I appreciate that. In that market, where are you seeing competition originate from?
Brent Zacharias
executiveSure, that's a fair question, and a number of Technologies have been putting out announcements regarding their development. What I would say is that the sole other options we observe in the marketplace right now are what I would describe as alternative sources derived from marine inputs — fish oil — which includes us, along with certain algal Technologies, where they ferment and generate various kinds of offerings from algal Technologies. The difficulty the industry, I believe, is encountering with algal Technologies is that they come at a very high cost, given the sort of technology needed to make them. During the COVID period, I think we observed that they faced considerable challenges, and we already know that we are beginning to take over some of the volumes of those alternative Technologies. I think the benefit we see in a plant-based source is employing agriculture as a highly efficient system that allows us to hold a competitive position and, probably most crucially, a scalable position. At this moment, we truly do not see any really meaningful competitive pressure from alternative Technologies in the market, and our opportunity is to assist the market in growing by being the leader in this space.
Matt Perry
unknownMuch appreciated — that’s genuinely useful.
Brent Zacharias
executiveI appreciate that.
Operator
operatorThanks. That brings us to the end of the Q&A. This now wraps up today's conference. We appreciate everyone joining us. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.